CMBA
IRWD icon

C.M. Bidwell & Associates’s Ironwood Pharmaceuticals IRWD Stock Holding History

C.M. Bidwell & Associates’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,360
Closed -$83K – 588
2021
Q3 		$83K Buy
+6,360
New +$82.2K 0.06% 249

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

C.M. Bidwell & Associates's IRWD Position: Q4 2021 in Review

C.M. Bidwell & Associates sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2021, closing a stake of 6,360 shares — an estimated $83K sold.

C.M. Bidwell & Associates first reported a position in IRWD in Q3 2021 and held it in 1 quarter. The position peaked at $83K in Q3 2021. 212 funds tracked by Wall St. Rank hold IRWD as of Q4 2021.

  • C.M. Bidwell & Associates reported no remaining Ironwood Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 6,360 Ironwood Pharmaceuticals shares in Q4 2021, an estimated $83K.
  • C.M. Bidwell & Associates first reported a position in Ironwood Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Ironwood Pharmaceuticals position peaked at $83K in Q3 2021.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2021.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2021, filed 11 Feb 2022.